Modeling influenza virus infection: a roadmap for influenza research

A Boianelli, VK Nguyen, T Ebensen, K Schulze, E Wilk… - Viruses, 2015 - mdpi.com
Influenza A virus (IAV) infection represents a global threat causing seasonal outbreaks and
pandemics. Additionally, secondary bacterial infections, caused mainly by Streptococcus …

Predictive markers of immunogenicity and efficacy for human vaccines

M Van Tilbeurgh, K Lemdani, AS Beignon, C Chapon… - Vaccines, 2021 - mdpi.com
Vaccines represent one of the major advances of modern medicine. Despite the many
successes of vaccination, continuous efforts to design new vaccines are needed to fight “old” …

Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis

J Malinzi, R Ouifki, A Eladdadi, DFM Torres… - arXiv preprint arXiv …, 2018 - arxiv.org
Oncolytic virotherapy (OV) has been emerging as a promising novel cancer treatment that
may be further combined with the existing therapeutic modalities to enhance their effects. To …

Dynamically linking influenza virus infection kinetics, lung injury, inflammation, and disease severity

MA Myers, AP Smith, LC Lane, DJ Moquin, R Aogo… - Elife, 2021 - elifesciences.org
Influenza viruses cause a significant amount of morbidity and mortality. Understanding host
immune control efficacy and how different factors influence lung injury and disease severity …

Influenza virus infection model with density dependence supports biphasic viral decay

AP Smith, DJ Moquin, V Bernhauerova… - Frontiers in …, 2018 - frontiersin.org
Mathematical models that describe infection kinetics help elucidate the time scales,
effectiveness, and mechanisms underlying viral growth and infection resolution. For …

serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes

A Menezes, S Takahashi, I Routledge… - PLoS computational …, 2023 - journals.plos.org
serosim is an open-source R package designed to aid inference from serological studies, by
simulating data arising from user-specified vaccine and antibody kinetics processes using a …

Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation

C Pasin, I Balelli, T Van Effelterre, V Bockstal… - Journal of …, 2019 - Am Soc Microbiol
The Ebola vaccine based on Ad26. ZEBOV/MVA-BN-Filo prime-boost regimens is being
evaluated in multiple clinical trials. The long-term immune response to the vaccine is …

Mathematical modelling of chemovirotherapy cancer treatment

SS Salim, J Malinzi, E Mureithi… - International Journal of …, 2023 - Taylor & Francis
This work investigates the synergistic effects of the combination of oncolytic virotherapy and
chemotherapy on tumour cells. A mathematical model, in the form of ordinary differential …

Rational vaccine design in times of emerging diseases: The critical choices of immunological correlates of protection, vaccine antigen and immunomodulation

V Schijns, D Majhen, P Van Der Ley, A Thakur… - Pharmaceutics, 2021 - mdpi.com
Vaccines are the most effective medical intervention due to their continual success in
preventing infections and improving mortality worldwide. Early vaccines were developed …

A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus

I Balelli, C Pasin, M Prague, F Crauste… - Journal of theoretical …, 2020 - Elsevier
Abstract The 2014–2016 Ebola outbreak in West Africa has triggered accelerated
development of several preventive vaccines against Ebola virus. Under the EBOVAC1 …